STADA Arzneimittel AG

STADA Arzneimittel AG

STADA Arzneimittel AG

Date Founded



Stadastrasse 2-18,Bad Vilbel, Hessen 61118

Type of Company


Employees (Worldwide)



Retail: Drug Stores

Company Description

STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the Generics and Branded Products segments. The Generics segment produces and distributes generic drugs. The Branded Products segment sells branded healthcare products and medicines. Its brands include Zoflora, Grippostad, Nizoral, and Covonia. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany.

Contact Data
Trying to get in touch with decision makers at STADA Arzneimittel AG? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer

Chief Technical Officer

Head of Europe

Executive Vice President, Head of Global Development, Portfolio, Regulatory & Business Development/Licensing

Executive Vice President Russia/CIS

Executive Vice President Global Human Resources

Executive Vice President Global Legal

Executive Vice President UK/US

Executive Vice President

Supervisory Board

Vice Chairman at Clariant International AG

Partner at Cinven Group Ltd.

Managing Director at Bain Capital Private Equity LP

Principal at Bain Capital Private Equity LP

Employee Representative at STADA Arzneimittel AG

Senior Principal at Cinven Group Ltd.

Professional at STADA Arzneimittel AG

Paths to STADA Arzneimittel AG
Potential Connections via
Relationship Science
STADA Arzneimittel AG
Owners & Shareholders
Details Hidden

Part of Butler Investment Managers Ltd., Butler Investment Advisors SAS is a company headquartered in Paris, France. The firm provides Investment Advice. It was founded in 2009. Olivier de Parcevaux is the current CEO of the firm.

Details Hidden

BN & Partners Capital AG, part of Reuss Private Group AG, is a German company located in Erftstadt. The firm provides investment advice. It was founded in 2004. Konstantinos Liolis and Mirko Siepmann are the current co-CEOs of the company.

Details Hidden

ProfitlichSchmidlin AG is a German private company located in Cologne that provides investment advice. The firm was founded in 2013 by Marc Profitlich and Nicolas Schmidlin. Marc Profitlich and Nicolas Schmidlin are the current co-CEOs of the company.

Recent Transactions
Details Hidden

STADA Arzneimittel AG purchases WALMARK as from Mid Europa Partners LLP

Details Hidden

STADA Arzneimittel AG, Thornton & Ross Ltd. purchase Glaxosmithkline Plc /Brands 6 from GlaxoSmithKline Plc

Details Hidden

Cinven Group Ltd., Bain Capital Private Equity LP, STADA Arzneimittel AG /Private Group purchase STADA Arzneimittel AG

Transaction Advisors
Legal Advisor

Advised onSTADA Arzneimittel AG purchases Nizhpharm OJSC

Legal Advisor

Advised onCinven Group Ltd., Bain Capital Private Equity LP, STADA Arzneimittel AG /Private Group purchase STADA Arzneimittel AG

Investment Advisor

Advised onSTADA Arzneimittel AG purchases LipoNova GmbH

Legal Advisor

Advised onCinven Group Ltd., Bain Capital Private Equity LP, STADA Arzneimittel AG /Private Group purchase STADA Arzneimittel AG


Advised onCinven Group Ltd., Bain Capital Private Equity LP, STADA Arzneimittel AG /Private Group purchase STADA Arzneimittel AG


China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the "Group") is a pharmaceutical services provider based in China, focusing on marketing promotion and sales of prescription drugs to all therapeutic departments in hospitals. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007, the Group was listed on Main Board Market in Hong Kong on 28 September 2010 while it was delisted on AIM at the same time. The Group follows two business models which can be commonly found in the pharmaceutical industry in China, the Direct Academic Orientated Promotion Model and Agency Promotion Model, and with two distinct third party promotion networks, the Direct Academic Orientated Promotion Network (the “Direct Network”) and the Agency Promotion Network (the “Agency Network”), both of which hold leading positions in the Chinese market. On the 3 April 2011, the Group successfully acquired Great Move Enterprise Limited (“Great Move”) and its subsidiaries, the main wholly subsidiary of Great Move is Tianjin Precede Medical Trade Development Co., Ltd.(which has been officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd.on 24 October 2011), which mainly engages in the marketing, promotion and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies via Agency Network in China. After the acquisition, the Group` business model evolved from simply depending on internal marketing and promotion team to promote and sell products directly to physicians (Direct Academic Orientated Promotion Model) to a new integrated development model that incorporates the independent third party sales representatives and distributors to sale and promote products (Agency Promotion Model) in China. On the 31 May 2011, the Group successfully acquired 51% equity interests of Guangming Pharmaceutical Co., Ltd. (which has been officially renamed Guangxi Kangzhe Guangming Pharmaceutical Co., Ltd. on 10 October 2011) via cash investment for capital and stock increase to gain the permanent China market rights of a type of enteral nutrition drug-“Protein Hydrolysate”. The speedy introduction of this product is the result of the combination of the professional academic ability from our Direct Network and the rapid market coverage ability of our Agency Network. We introduce drugs that prove to be competitive and focus on providing marketing, promotion and sales services to specialty pharmaceutical companies by leveraging our successful product selection system and the insights in Chinese pharmaceutical market. As at 31 December 2011, the Direct Network of the Group had close to 1,200 sales, marketing and promotion professionals; the Agency Network had close to 1,000 independent third party sales representatives or distributors and around a hundred of senior regional and marketing managers. The Group`s sales coverage spanned over 14,600 hospitals throughout China, of which almost 8,600 hospitals were covered by the Direct Network and over 7,800 hospitals were covered by the Agency Network. The Group follows a market-oriented product selection strategy and introduces prescription drugs with high growth potential under its Direct Academic Orientated Promotion Model. We formulate appropriate marketing strategies for each drug, leveraging the insights in the Chinese pharmaceutical market, prevailing treatment protocols of physicians, demographic profile of the relevant patient pool in China and potential competitive advantages of drugs. Meanwhile, in order to help drive demand for pharmaceutical products, our professional, stable and experienced marketing, promotion and sales team conducts various physician-oriented academic promotion activities such as one-on-one physician visits, medical symposia and industry conferences, and via our proprietary information management system to keep track of these activities and review operations in a timely manner, enabling us to manage our overall business effectively and efficiently. In addition, the Group also provides other ancillary services needed by pharmaceutical companies to introduce their products to China, including handling product registration, clinical trials, and bidding in collective tender processes. With appropriate product positioning, strategic planning and execution, the Group gained remarkable performance. From 2007 to 2011, the compound annual growth rate (CAGR) of revenue was 42.0%, and the CAGR of net profit achieved 63.7%. We also received a number of recognitions, including the Group was ranked in the list of Forbes “Asia’s Best 200 Enterprises Under a Billion” in 2008 and “Top 100 Enterprises in Shenzhen” in 2009, 2010 and 2011, and we also gained Forbes “China’s Best Up-and-Coming Business” three times in 2010, 2011 and 2012. As a leading China-based pharmaceutical services company, the Group established long-term business partnership with specialty pharmaceutical companies from Germany, Denmark, Ireland, France, Ukraine, Japan and China. We will continuously introduce new products and extend marketing, promotion and sales network to strengthen our leading position in Chinese pharmaceutical service market, and through the professional and quality service to catch opportunities from the enormous growth of Chinese pharmaceutical market and strives to become the preferred partner for overseas and domestic pharmaceutical companies who target at Chinese market.

Pymepharco JSC engages in the manufacture and distribution of pharmaceutical products. Its products include biotins, kisinstad, combistad, pyfaclor, pyfaclor and bioequivalence. The company was founded on July 23, 1989 and is headquartered in Tuy Hoa, Vietnam.

Sanacorp Pharmaholding AG operates as a holding company, which engages in the supply of pharmaceutical and healthcare products. It also provides logistics, quality management, and marketing services. The company was founded on November 7, 1995 and is headquartered in Planegg, Germany.

Key Stats and Financials As of 2019
Market Capitalization
Total Enterprise Value
Earnings Per Share
Total Equity
Total Debt
Net Profit
Debt TEV
TEVNet Income
Enterprise Value EBITDAOperating
Enterprise Value / Sales
Five Year Compounded Annual Growth Rate Of Revenue
Three Year Compounded Annual Growth Rate Of Revenue
Details Hidden

Kinostics SpA develops and manufactures pharmaceutical products. The company was founded by Carlos Irarrázabal in 2012 and is headquartered in Santiago, Chile.

The Chemical Works of Gedeon Richter Plc Pharmaceuticals | Budapest, Hungary

The Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale and Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale and Retail segment represents the distribution chain in the market which facilitate the product reaching the final buyers. The Other segment relates to the business of the members of the group that do not belong to any of the segments. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

DCC Plc Food | Foxrock, Ireland

DCC Plc provides international sales, marketing, and business support services. It operates through the following segments: DCC LPG, DCC Retail & Oil, DCC Healthcare, and DCC Technology. The DCC LPG segment operates a liquefied petroleum gas (LPG) sales and marketing business with operations in Europe, Asia, and the US with a developing business in the retailing of natural gas and electricity. The DCC Retail & Oil segment is involved in the sales, marketing, and retailing of transport and commercial fuels, heating oils, and related products and services in Europe. The DCC Healthcare segment provides products and services to healthcare providers and health and beauty brand owners. The DCC Technology segment serves as a route-to-market and supply chain partner for global technology brands. The company was founded by Jim Flavin in 1976 and is headquartered in Dublin, Ireland.

Futura Medical Plc Medical Support Services | Guildford, United Kingdom

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. It also focuses on developing products for sexual healthcare and pain relief. The Sexual Healthcare products comprise MED2002. The Pain Relief products comprises TPR100 and TIB200. The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by STADA Arzneimittel AG. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of STADA Arzneimittel AG's profile does not indicate a business or promotional relationship of any kind between RelSci and STADA Arzneimittel AG.